Retailers, consumers and prices
Check out federal regulator’s warning to green tea sellers.
The U.S. Food and Drug Administration issued warning letters to Dr Pepper Snapple Group and Unilever over their use of health claims to sell green tea products.
The agency, which regularly sends warning letters to companies that have violating manufacturing, marketing and testing requirements, took issue with Dr Pepper Snapple Group’s claim that its Canada Dry Green Tea Ginger Ale is “enhanced with 200 mg of antioxidants from green tea and Vitamin C”. FDA said the statement did not comply with rules governing nutrient content claims.
In its letter to Unilever, FDA said the company violated the Federal Food, Drug and Cosmetic Act with claims that consuming green tea, like its Lipton decaffeinated green tea, can help lower cholesterol.
“The therapeutic claims on your website establish that the product is a drug because it is intended for use in the cure, mitigation, treatment, or prevention of disease. Your Lipton Green Tea 100% Natural Naturally Decaffeinated product is not generally recognized as safe and effective for the above referenced uses and, therefore, the product is a ‘new drug’ … New drugs may not be legally marketed in the U.S. without prior approval from FDA,” the agency said.